Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 6, 2006, Pages

  Grobe, Justin L ^a   Mecca, Adam P ^a   Mao, Haoyu ^a   Katovich, Michael J ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Blood pressure; Cardiac remodeling; Deoxycorticosterone acetate

Indexed keywords

ANGIOTENSIN I; DEOXYCORTICOSTERONE ACETATE; DRINKING WATER; PARAFFIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE; CANNULATION; CAROTID ARTERY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; HEART MUSCLE FIBROSIS; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; METHODOLOGY; MUSCLE CELL; NONHUMAN; OSMOTIC MINIPUMP; PELLET EXTRUSION; PRIORITY JOURNAL; RAT; RAT STRAIN; STAINING; UNINEPHRECTOMY;

ANGIOTENSIN I; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; COLLAGEN; CORONARY VESSELS; DESOXYCORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; HEART DISEASES; HYPERTENSION; MALE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 33744910056     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01170.2005     Document Type: Article

References (70)

1. Abraham G and Simon G. Autopotentiation of pressor responses by subpressor angiotensin II in rats. Am J Hypertens 7: 269-275, 1994.
2. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, and Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324: 1098-1104, 1991.
3. Anderson S, Rennke HG, and Brenner BM. Advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986.
4. Averill DB, Ishiyama Y, Chappell MC, and Ferrario CM. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108: 2141-2146, 2003.
5. Bayorh MA, Eatman D, Walton M, Socci RR, Thierry-Palmer M, and Emmett N. A-779 attenuates angiotensin-(1-7) depressor response in salt-induced hypertensive rats. Peptides 23: 57-64, 2002.
6. Benetos A, Lacolley P, and Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 17: 1152-1156, 1997.
7. Benter IF, Diz DI, and Ferrario CM. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 26: 1138-1144, 1995.
8. Brilla CG, Janicki JS, and Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69: 107-115, 1991.
9. Brilla CG and Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120: 893-901, 1992.
10. Brosnihan KB, Li P, and Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523-528, 1996.
11. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, and Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441-449, 1972.
12. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, and Johnston CI. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26: 369-375, 2005.
13. Crabos M, Roth M, Hahn AW, and Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest 93: 2372-2378, 1994.
14. Davie AP and McMurray JJ. Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 34: 457-460, 1999.
15. Dobrzynski E, Wang C, Chao J, and Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 36: 995-1001, 2000.
16. Eatman D, Wang M, Socci RR, Thierry-Palmer M, Emmett N, and Bayorh MA. Gender differences in the attenuation of salt-induced hypertension by angiotensin (1-7). Peptides 22: 927-933, 2001.
17. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, and Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-2610, 2005.
18. Ferreira AJ, Santos RA, and Almeida AP. Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. Braz J Med Biol Res 35: 1083-1090, 2002.
19. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 28: 1002-1006, 2001.
20. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, and Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2. Exp Physiol 90: 783-790, 2005.
21. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, and Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate anti-fibrotic and anti-trophic effects. Am J Physiol Heart Circ Physiol 289: H2356-H2363, 2005.
22. Iyer SN, Chappell MC, Averill DB, Diz DI, and Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31: 699-705, 1998.
23. Jalil JE, Janicki JS, Pick R, and Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril. Am J Hypertens 4: 51-55, 1991.
24. Katovich MJ, Reaves PY, Francis SC, Pachori AS, Wang HW, and Raizada MK. Gene therapy attenuates the elevated blood pressure and glucose intolerance in an insulin-resistant model of hypertension. J Hypertens 19: 1553-1558, 2001.
25. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, and Abassi Z. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97: 946-953, 2005.
26. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, and Iwao H. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24: 195-204, 1994.
27. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, Bathgate RA, Du XJ, and Samuel CS. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46: 412-418, 2005.
28. Le Tran Y and Forster C. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol 30: 676-682, 1997.
29. Lijnen P and Petrov V. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Exp Clin Pharmacol 21: 215-227, 1999.
30. Lijnen PJ, Petrov VV, and Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst 2: 117-122, 2001.
31. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, and van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105: 1548-1550, 2002.
32. Lu D, Raizada MK, Iyer S, Reaves P, Yang H, and Katovich MJ. Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension 30: 363-370, 1997.
33. Melargno M and Fink G. Inhibition of the slow pressor effect of angiotensin II contributes to the antihypertensive effect of angiotensin converting enzyme inhibitors in renovascular hypertension. J Pharmacol Exp Ther 278: 297-303, 1996.
34. Mendes AC, Ferreira AJ, Pinheiro SV, and Santos RA. Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. Regul Pept 125: 29-34, 2005.
35. Nehme JA, Lacolley P, Labat C, Challande P, Robidel E, Perret C, Leenhardt A, Safar ME, Delcayre C, and Milliez P. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol 39: 511-519, 2005.
36. Neves LA, Averill DB, Ferrario CM, Aschner JL, and Brosnihan KB. Vascular responses to angiotensin-(1-7) during the estrous cycle. Endocrine 24: 161-165, 2004.
37. 1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens 12: 301-309, 1998.
38. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, and Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial The SAVE Investigators. N Engl J Med 327: 669-677, 1992.
39. Pinto YM, de Smet BG, van Gilst WH, Scholtens E, Monnink S, de Graeff PA, and Wesseling H. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 27: 1933-1938, 1993.
40. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
41. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, and Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747-752, 1997.
42. Rasband WS ImageJ [Online]. U.S. National Institutes of Health, Bethesda, MD. http://rsb.info.nih.gov/ij [1997-2005].
43. Ren Y, Garvin JL, and Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39: 799-802, 2002.
44. Rocha R and Stier CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12: 308-314, 2001.
45. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, and Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878, 2000.
46. Sampaio WO, Nascimento AA, and Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 284: H1985-H1994, 2003.
47. Santos RA, Brum JM, Brosnihan KB, and Ferrario CM. The renin-angiotensin system during acute myocardial ischemia in dogs. Hypertension 15: I121-I127, 1990.
48. Santos RA, Campagnole-Santos MJ, and Andrade SP Angiotensin-(1-7): an update. Regul Pept 91: 45-62, 2000.
49. Santos RA, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, Baltatu O, Iliescu R, Reudelhuber TL, and Bader M. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 17: 292-299, 2004.
50. Sasaki S, Higashi Y, Nakagawa K, Matsuura H, Kajiyama G, and Oshima T. Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension 38: 90-94, 2001.
51. Schunkert H, Tang SS, Litwin SE, Diamant D, Riegger G, Dzau VJ, and Ingelfinger JR. Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. Cardiovasc Res 27: 731-735, 1993.
52. Simon G, Abranham G, and Cserep G. Pressor and subpressor angiotensin II administration. Two experimental models of hypertension. Am J Hypertens 8: 645-650, 1995.
53. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691, 1992.
54. Stegbauer J, Vonend O, Oberhauser V, and Rump LC. Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney. J Hypertens 21: 1391-1399, 2003.
55. Stier CT Jr, Chander P, Gutstein WH, Levine S, and Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 4: 680-687, 1991.
56. Stier CT Jr, Adler LA, Levine S, and Chander PN. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens Suppl 11: S37-S42, 1993.
57. Stier CT, Jr, Benter IF, Ahmad S, Zuo HL, Selig N, Roethel S, Levine S, and Itskovitz HD. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 13: 115-121, 1998.
58. Takeda Y, Yoneda T, Demura M, Usukura M, and Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 105: 677-679, 2002.
59. Tallant EA, Ferrario CM, and Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-H1566, 2005.
60. Thurmann PA, Kenedi P, Schmidt A, Harder S, and Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 98: 2037-2042, 1998.
61. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15: 264-272, 2000.
62. Weber KT and Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865, 1991.
63. Weber KT. Hormones and fibrosis: a case for lost, reciprocal regulation. News Physiol Sci 9: 123-128, 1994.
64. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 345: 1689-1697, 2001.
65. Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, and Brown NJ. Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension 37: 1136-1140, 2001.
66. Young M and Funder JW. Aldosterone and the heart. Trends Endocrinol Metab 11: 224-226, 2000.
67. Young M and Funder J. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology 144: 3848-3851, 2003.
68. Young M, Fullerton M, Dilley R, and Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93: 2578-2583, 1994.
69. Young M, Head G, and Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol Endocrinol Metab 269: E657-E662, 1995.
70. Zhu Z, Zhong J, Zhu S, Liu D, Van Der Giet M, Tepel Zhu Z M, Zhong J, Zhu S, Liu D, Van Der Giet M, and Tepel M. Angiotensin- (1-7) inhibits angiotensin II-induced signal transduction. J Cardiovasc Pharmacol 40: 693-700, 2002.